Literature DB >> 11519923

Surveillance of hospital-acquired infection in England, Germany, and The Netherlands: will international comparison of rates be possible?

R Coello1, P Gastmeier, A S de Boer.   

Abstract

Three national surveillance systems for nosocomial infection have been developed independently and implemented successfully in England, Germany, and The Netherlands. All three are based on the American National Nosocomial Infections Surveillance System and have adopted a surveillance strategy that is targeted at specific infections or groups of patients for limited time periods. Case-finding methods, the minimum data set, and analysis of data are similar and could be standardized easily. Resolution of the differences in the definitions of infection, the study population, and follow-up should make possible the international comparison of infection rates. Such comparisons may identify differences in healthcare practices between countries and suggest areas for improvement.

Entities:  

Mesh:

Year:  2001        PMID: 11519923     DOI: 10.1086/501923

Source DB:  PubMed          Journal:  Infect Control Hosp Epidemiol        ISSN: 0899-823X            Impact factor:   3.254


  3 in total

1.  A preliminary study for the development of indices and the current state of surgical site infections (SSIs) in Korea: the Korean Surgical Site Infection Surveillance (KOSSIS) program.

Authors:  Sun Jin Park; Kil Yeon Lee; Ji Won Park; Jae Gil Lee; Hee Jung Choi; Hee Kyung Chun; Jung Gu Kang
Journal:  Ann Surg Treat Res       Date:  2015-02-27       Impact factor: 1.859

2.  Surveillance length and validity of benchmarks for central line-associated bloodstream infection incidence rates in intensive care units.

Authors:  Patricia S Fontela; Caroline Quach; David Buckeridge; Madukhar Pai; Robert W Platt
Journal:  PLoS One       Date:  2012-05-07       Impact factor: 3.240

3.  Process quality indicators in family medicine: results of an international comparison.

Authors:  Danica Rotar Pavlič; Maja Sever; Zalika Klemenc-Ketiš; Igor Švab
Journal:  BMC Fam Pract       Date:  2015-12-02       Impact factor: 2.497

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.